- |||||||||| Niagen (nicotinamide riboside) / ChromaDex
Clinical, Journal: Sarcopenia, aging and prospective interventional strategies. (Pubmed Central) - Mar 27, 2019 Many naturally-occurring compounds, derived from commonly consumed foods, possess anti-sarcopenic effects, such asnicotinamide riboside, tomatidine, and Urolithin A. These naturally-occurring compounds can improve mitochondrial health and efficiency by modulating mitochondrial biogenesis, cellular stress resistance, or mitophagy. Further research should assess whether compounds that improve mitochondrial health can attenuate sarcopenia in humans.
- |||||||||| Biomarker, Clinical, Journal: Bone, muscle, and metabolic parameters predict survival in patients with synchronous bone metastases from lung cancers. (Pubmed Central) - Mar 27, 2019
In patients with lung adenocarcinoma and synchronous bone metastases, bone, sarcopenia, and metabolic parameters were predictors of poor overall survival independently of common prognostic factors. We suggest that, in addition to oncological therapy, supportive treatment dedicated to bone metastases, muscle wasting, and energy metabolism are essential to improve prognosis.
- |||||||||| Journal: Sarcopenia and outcomes in ventral hernia repair: a preliminary review. (Pubmed Central) - Mar 27, 2019
Previously established sarcopenia outcomes in malignancy may be attributable to an altered metabolic state that is not present in hernia repair patients. Larger-scale studies are recommended to establish new sarcopenia cutoffs for VHRs.
- |||||||||| Clinical, Review, Journal: Nutritional interventions in elderly gastrointestinal cancer patients: the evidence from randomized controlled trials. (Pubmed Central) - Mar 27, 2019
Nutritional and clinical benefits were reported with the use of ω-3 fatty acid-enriched oral supplements and especially with long-term supplemental parenteral nutrition. Despite the general recommendation of the scientific community that emphasizes the use of the enteral route, whenever possible, for delivering the nutritional support, it appears from the literature that more consistent benefits can be achieved, especially in the long-term nutritional support, when an insufficient oral nutrition is partnered with intravenous nutrition.
- |||||||||| Journal: Hybrid fiber alterations in exercising seniors suggest contribution to fast-to-slow muscle fiber shift. (Pubmed Central) - Mar 26, 2019
Exercise intervention increased Type I-IIa hybrid fibers along with shift dynamics in other fiber types suggesting the contribution of hybrid fiber to a fast-to-slow fiber type transition, eventually serving as intermediate reservoir from one monomorphic myosin heavy chain expressing fiber type to another. This finding favours the transitional theory regarding hybrid muscle fibers and exercise, crucial to understanding reversible mechanisms of sarcopenia and development of prevention measures.
- |||||||||| Enrollment closed: Leucine Supplementation in Sarcopenic Older Individuals (clinicaltrials.gov) - Mar 22, 2019
P1, N=59, Active, not recruiting, Both the presence and rate of change of sarcopenia are independently associated with long-term mortality in patients with liver cirrhosis. Recruiting --> Active, not recruiting
- |||||||||| NN1213 / Novo Nordisk
Trial completion, Trial primary completion date: Implementing Resistance Exercise to Reduce Frailty for Older Adult (clinicaltrials.gov) - Mar 13, 2019 P=N/A, N=126, Completed, Enrolling by invitation --> Active, not recruiting Active, not recruiting --> Completed | Trial primary completion date: Jun 2018 --> Aug 2017
- |||||||||| Trial completion, Trial completion date, Trial primary completion date: Beta-Hydroxy-Beta-Methylbutyrate (HMB) Supplementation After Liver Transplantation (clinicaltrials.gov) - Mar 11, 2019
P=N/A, N=22, Completed, Skeletal muscle index and density provide independent, complementary information, and the product of the two metrics, skeletal muscle gauge, requires further research to explore its impact on outcomes in women with curable breast cancer. Recruiting --> Completed | Trial completion date: Dec 2017 --> Sep 2018 | Trial primary completion date: Dec 2017 --> Sep 2018
- |||||||||| Enrollment closed, Trial initiation date: ENSASL: Exercise and Nutritional Supplementation (clinicaltrials.gov) - Mar 8, 2019
P=N/A, N=80, Active, not recruiting, Increasing lean body mass may serve as a tangible target in mitigating the high cardiometabolic risks of HCT survivors. Not yet recruiting --> Active, not recruiting | Initiation date: Sep 2018 --> Jun 2018
- |||||||||| Syntocinon Nasal Spray (oxytocin intranasal) / Vyera Pharma
Enrollment closed, Enrollment change, Trial completion date: INOSO: The Physiologic Effects of Intranasal Oxytocin on Sarcopenic Obesity (clinicaltrials.gov) - Feb 27, 2019 P1/2, N=25, Active, not recruiting, Trial completion date: Dec 2018 --> Oct 2019 | Trial primary completion date: Dec 2018 --> Aug 2019 Recruiting --> Active, not recruiting | N=36 --> 25 | Trial completion date: Sep 2019 --> Dec 2019
- |||||||||| goserelin acetate / Generic mfg.
Enrollment closed, Trial completion date: Systemic Hormones and Muscle Protein Synthesis (clinicaltrials.gov) - Feb 26, 2019 P3, N=34, Active, not recruiting, Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial completion date: Dec 2019 --> Feb 2019
- |||||||||| Trial completion date, Trial primary completion date: Exercise Intervention - and Impact on Hospitalization (clinicaltrials.gov) - Feb 21, 2019
P=N/A, N=32, Recruiting, Recruiting --> Active, not recruiting | Trial completion date: Dec 2019 --> Feb 2019 Trial completion date: Jan 2019 --> Jan 2020 | Trial primary completion date: Jan 2019 --> Jan 2020
- |||||||||| Trial completion date, Trial primary completion date: MASS: Prevalence of Malnutrition and/or Sarcopenia at Hospital Admission (clinicaltrials.gov) - Feb 21, 2019
P=N/A, N=100, Recruiting, Trial completion date: Jan 2019 --> Jan 2020 | Trial primary completion date: Jan 2019 --> Jan 2020 Trial completion date: Jan 2020 --> Jan 2022 | Trial primary completion date: Jan 2019 --> Jan 2021
- |||||||||| Trial completion date, Trial primary completion date: Impact of Whole-body Vibration Training on Sarcopenic Elderly (clinicaltrials.gov) - Feb 15, 2019
P=N/A, N=40, Recruiting, Recruiting --> Completed Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Oct 2019
- |||||||||| NN1213 / Novo Nordisk
Trial completion, Trial completion date: Nutritional Intervention for Age-related Muscular Function and Strength Losses-Study 2 (clinicaltrials.gov) - Feb 11, 2019 P1, N=238, Completed, Trial completion date: Sep 2018 --> Apr 2020 | Initiation date: Jul 2018 --> Apr 2019 | Trial primary completion date: Aug 2018 --> Apr 2020 Active, not recruiting --> Completed | Trial completion date: Aug 2019 --> Feb 2019
|